These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 1196872)

  • 1. [The deterioration of patients with parkinsonism treated with L-dopa].
    Guillard A
    Nouv Presse Med; 1975 Oct; 4(35):2503-6. PubMed ID: 1196872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Outcome of Parkinsonism after two years of levodopa plus R04-4602 (author's transl)].
    Faglioni P; Gasparini M; Spinnler H
    Riv Patol Nerv Ment; 1975; 96(4):270-86. PubMed ID: 785578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. L-dopa, parkinsonism, and involuntary movements.
    Mayer RF
    Trans Am Neurol Assoc; 1974; 99():163-6. PubMed ID: 4463527
    [No Abstract]   [Full Text] [Related]  

  • 4. [Results after 3 to 5 years of treatment of 219 cases of Parkinson's syndrome treated by L-Dopa and an L-Dopa -decarboxylase inhibitor combination].
    Boudin G; Pepin B; Guillard A; Godlewski S; Fabiani JM; Haguenau M
    Rev Neurol (Paris); 1974; 130(7-8):273-84. PubMed ID: 4217929
    [No Abstract]   [Full Text] [Related]  

  • 5. [Long-term prognostic factors in Parkinson's disease (author's transl)].
    Guillard A; Chastang C
    Rev Neurol (Paris); 1978 May; 134(5):341-54. PubMed ID: 725403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The "on-off" response to chronic L-DOPA treatment of Parkinsonism.
    Sweet RD; McDowell FH
    Adv Neurol; 1974; 5():331-8. PubMed ID: 4440581
    [No Abstract]   [Full Text] [Related]  

  • 7. [Long-term l-DOPA therapy for parkinsonism and its pathochemical aspect].
    Petelin LS; Vartanian KZ; Romenskaia LKh
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1977; 77(12):1810-3. PubMed ID: 602554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Individual manifestations of Parkinson's disease after ten or more years of levodopa.
    Klawans HL
    Mov Disord; 1986; 1(3):187-92. PubMed ID: 3504244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Levodopa as a single treatment of Parkinsonism. Long-term control of 24 cases with discrimination analysis].
    Borromei A; Manzini A
    Minerva Med; 1974 Nov; 65(79):4160-70. PubMed ID: 4610450
    [No Abstract]   [Full Text] [Related]  

  • 10. Treatment of Parkinson's disease: levodopa as the first choice.
    Katzenschlager R; Lees AJ
    J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of treatment with levodopa on Parkinson's disease.
    Shaw KM; Lees AJ; Stern GM
    Q J Med; 1980; 49(195):283-93. PubMed ID: 7465763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Diagnosis and course (under treatment) of Parkinson disease].
    Fénelon G
    Rev Prat; 1997 May; 47(10):1062-7. PubMed ID: 9208668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effectiveness of slow release L-DOPA/benserazide in treatment of end-of-dose akinesia in Parkinson disease].
    Eichhorn TE; Schrag A; Trenkwalder C; Selzer R; Kohnen R; Oertel WH; Poewe W
    Nervenarzt; 1995 Dec; 66(12):933-41. PubMed ID: 8584079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accuracy of acute levodopa challenge for clinical prediction of sustained long-term levodopa response as a major criterion for idiopathic Parkinson's disease diagnosis.
    Merello M; Nouzeilles MI; Arce GP; Leiguarda R
    Mov Disord; 2002 Jul; 17(4):795-8. PubMed ID: 12210878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.
    Parkinson Study Group CALM Cohort Investigators
    Arch Neurol; 2009 May; 66(5):563-70. PubMed ID: 19433655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Intellectual deterioration in Parkinson patients treated with L-dopa. Long-term prognostic factors].
    Bonduelle M; Degos CF
    Int J Neurol; 1979; 13(1-4):255-61. PubMed ID: 263185
    [No Abstract]   [Full Text] [Related]  

  • 17. [Abnormal movements induced by L-dopa. New therapeutic possibilities].
    Eisenring J-J ; Constantinidis J; Dick P; Yanniotis G; Tissot R
    Schweiz Med Wochenschr; 1975 Jan; 105(4):121-4. PubMed ID: 1124379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dystonia--L-dopa responsive or juvenile parkinsonism?
    Rondot P; Ziegler M
    J Neural Transm Suppl; 1983; 19():273-81. PubMed ID: 6583312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Long-term study of 416 cases of Parkinson disease. Prognostic factors and therapeutic implications].
    Guillard A; Chastang C; Fenelon G
    Rev Neurol (Paris); 1986; 142(3):207-14. PubMed ID: 3797924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years.
    Hely MA; Morris JG; Reid WG; Trafficante R
    Mov Disord; 2005 Feb; 20(2):190-9. PubMed ID: 15551331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.